NCT07415005 2026-02-17
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
Clinical Trials
7 trialsNCT07083687 2025-07-24
Lorlatinib in ROS1+ NSCLC With Brain Metastasis
Hunan Cancer Hospital
Phase 2 Not yet recruiting
NCT06893354 2025-03-25
Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics
The First Affiliated Hospital of Guangzhou Medical University
Phase 4 Not yet recruiting
NCT06858410 2025-03-05
Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma
Guangdong Association of Clinical Trials
Phase 3 Not yet recruiting
NCT06690541 2024-11-15
COMLORLA
Peking University Cancer Hospital & Institute
Not yet recruiting
NCT06682884 2024-11-12
NEOLORA
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT06282874 2024-02-28
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
Guangdong Association of Clinical Trials
Phase 4 Not yet recruiting